Fulcrum Therapeutics Inc (FULC) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Fulcrum Therapeutics Inc $3.79, price $3.81, upside -0.5%, quality 16 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Fulcrum Therapeutics Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $2.26 – $30.97 · fair‑value band $2.50 – $4.74 · the $3.81 price screens above the $3.79 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Fulcrum Therapeutics in your weekly email
Every Wednesday you see whether Fulcrum Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Show more
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Stock analysis
Fulcrum Therapeutics Inc (FULC) currently trades at $3.81, while our model-based Fair Value estimate is $3.79, implying the stock looks roughly 0.5% fairly valued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $2.50 (bear) to $4.74 (bull), the price of $3.81 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 16/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Fulcrum Therapeutics Inc reported revenue of $0 in FY2025 versus $19.2M in FY2021. Reported net income was −$74.9M in FY2025.
Key figures
Market cap $291M · EPS (TTM) $−1.21 · Return on equity −32.4% · Return on assets (EBIT) −31.7% · Free cash flow −$60.4M · Net cash $191M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).
What moves the price
The share trades about 74% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −1%, FULC screens cheaper than that median.
Fair Value models
Bear $2.50Fair Value $3.79Bull $4.74
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.32/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+2,752.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+61.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+154.5%
’19
’20
’21
’22
’23
’24
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−11,228.9% (2019) → −27.4% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Fulcrum Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks
Beats the industry median on 3/5 measures
Overall it ranks above its industry peers.
Valuation
Quality Score26 · Bottom 25%
Fair Value upside−1% · Above median
Profitability
Return on assets−20% · Below median
Operating margin (TTM)0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Fulcrum Therapeutics Inc (FULC) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $3.79 versus a price of $3.81, about −1% upside (fairly valued).
What is the fair value of FULC?
Our model-based fair value for Fulcrum Therapeutics Inc is $3.79 (as of Sep 24, 2026), built from audited fundamentals. The current price: $3.81.
What is the quality score of FULC?
Fulcrum Therapeutics Inc has a Quality Score of 16/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Fulcrum Therapeutics Inc (FULC)?
Our model-based price target is the fair value of $3.79 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $2.50, optimistic scenario $4.74. It is a calculation from audited fundamentals, not an analyst target.
What is the Fulcrum Therapeutics Inc stock forecast for 2026?
Our models put fair value at $3.79, about −1% upside versus a price of $3.81 (fairly valued). Cautious scenario $2.50, optimistic scenario $4.74. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Fulcrum Therapeutics Inc (FULC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Fulcrum Therapeutics Inc it is $3.79 per share (as of Sep 24, 2026), against a price of $3.81. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Fulcrum Therapeutics Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, FULC trades above its calculated fair value: price $3.81, fair value $3.79, a gap of about −1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of FULC?
No. The price is what the market pays today ($3.81); the fair value is what the company's own numbers justify ($3.79). For Fulcrum Therapeutics Inc the two are $0.0190 per share apart. That gap is exactly why we show both numbers side by side.
How much is Fulcrum Therapeutics Inc worth?
The market values Fulcrum Therapeutics Inc at about $291M (market capitalisation, as of Sep 24, 2026). Per share that is $3.81; our models calculate a fair value of $3.79 per share.
What do the bullish and bearish scenarios say about FULC?
Our models span a range for Fulcrum Therapeutics Inc: cautious scenario $2.50, base $3.79, optimistic $4.74 per share (as of Sep 24, 2026, price $3.81). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Fulcrum Therapeutics Inc (FULC)?
Balance-sheet figures for Fulcrum Therapeutics Inc (as of Sep 24, 2026): return on equity −32.4%. They feed the Quality Score of 16/100, which measures business quality independently of the share price.
How far is FULC from its 52-week high?
Fulcrum Therapeutics Inc trades at $3.81, about 74% below its 52-week high of $14.60 and 21% above the low of $3.14 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $3.79 is for.
Which stocks are comparable to Fulcrum Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Fulcrum Therapeutics Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $3.81, calculated fair value $3.79 (−1%), Quality Score 16/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of FULC calculated?
We run Fulcrum Therapeutics Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.79, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Fulcrum Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Fulcrum Therapeutics Inc (FULC)?
The closing price on Sep 23, 2026 was $3.81. Our model-based fair value is $3.79, about −1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Fulcrum Therapeutics Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($2.50 to $4.74) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Fulcrum Therapeutics Inc
How large is the market capitalisation of Fulcrum Therapeutics Inc (FULC)?
The market capitalisation of Fulcrum Therapeutics Inc is $291M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Fulcrum Therapeutics Inc (FULC)?
Earnings per share at Fulcrum Therapeutics Inc are $−1.21. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Fulcrum Therapeutics Inc (FULC)?
The return on equity (ROE) of Fulcrum Therapeutics Inc is −32.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Fulcrum Therapeutics Inc (FULC)?
On an EBIT basis the return on assets of Fulcrum Therapeutics Inc is −31.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Fulcrum Therapeutics Inc (FULC) generate?
The free cash flow of Fulcrum Therapeutics Inc is −$60.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Fulcrum Therapeutics Inc (FULC) hold?
Fulcrum Therapeutics Inc holds more cash than debt, $191M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Fulcrum Therapeutics Inc in the live analysis
One click puts Fulcrum Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026